BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 20577141)

  • 21. The null genotype of glutathione s-transferase M1 and T1 locus increases the risk for thyroid cancer.
    Morari EC; Leite JL; Granja F; da Assumpção LV; Ward LS
    Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1485-8. PubMed ID: 12433731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glutathione S-transferase M1, T1, and P1 polymorphisms and survival among lung cancer patients.
    Sweeney C; Nazar-Stewart V; Stapleton PL; Eaton DL; Vaughan TL
    Cancer Epidemiol Biomarkers Prev; 2003 Jun; 12(6):527-33. PubMed ID: 12814998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polymorphisms of the glutathione S-transferase P1 gene and head and neck cancer susceptibility.
    Oude Ophuis MB; Roelofs HM; van den Brandt PA; Peters WH; Manni JJ
    Head Neck; 2003 Jan; 25(1):37-43. PubMed ID: 12478542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma.
    Pasello M; Michelacci F; Scionti I; Hattinger CM; Zuntini M; Caccuri AM; Scotlandi K; Picci P; Serra M
    Cancer Res; 2008 Aug; 68(16):6661-8. PubMed ID: 18701490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liver disease in pediatric patients with cystic fibrosis is associated with glutathione S-transferase P1 polymorphism.
    Henrion-Caude A; Flamant C; Roussey M; Housset C; Flahault A; Fryer AA; Chadelat K; Strange RC; Clement A
    Hepatology; 2002 Oct; 36(4 Pt 1):913-7. PubMed ID: 12297838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polymorphisms of CYP1A1 and glutathione S-transferase and susceptibility to adult acute myeloid leukemia.
    D'Alò F; Voso MT; Guidi F; Massini G; Scardocci A; Sica S; Pagano L; Hohaus S; Leone G
    Haematologica; 2004 Jun; 89(6):664-70. PubMed ID: 15194533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. No evidence for glutathione S-transferases GSTA2, GSTM2, GSTO1, GSTO2, and GSTZ1 in breast cancer risk.
    Andonova IE; Justenhoven C; Winter S; Hamann U; Baisch C; Rabstein S; Spickenheuer A; Harth V; Pesch B; Brüning T; Ko YD; Ganev V; Brauch H
    Breast Cancer Res Treat; 2010 Jun; 121(2):497-502. PubMed ID: 19859803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional glutathione S-transferase genotypes among testicular germ cell tumor survivors: associations with primary and post-chemotherapy tumor histology.
    Kraggerud SM; Oldenburg J; Alnaes GI; Berg M; Kristensen VN; Fossa SD; Lothe RA
    Pharmacogenet Genomics; 2009 Oct; 19(10):751-9. PubMed ID: 19741569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Polymorphisms in detoxification genes CYP1A1, CYP2E1, GSTT1 and GSTM1 in gastric cancer susceptibility].
    González A; Ramírez V; Cuenca P; Sierra R
    Rev Biol Trop; 2004 Sep; 52(3):591-600. PubMed ID: 17361553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genomic alterations and allelic imbalances are strong prognostic predictors in osteosarcoma.
    Smida J; Baumhoer D; Rosemann M; Walch A; Bielack S; Poremba C; Remberger K; Korsching E; Scheurlen W; Dierkes C; Burdach S; Jundt G; Atkinson MJ; Nathrath M
    Clin Cancer Res; 2010 Aug; 16(16):4256-67. PubMed ID: 20610556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined polymorphism analysis of glutathione S-transferase M1/G1 and interleukin-1B (IL-1B)/interleukin 1-receptor antagonist (IL-1RN) and gastric cancer risk in an Omani Arab Population.
    Al-Moundhri MS; Alkindy M; Al-Nabhani M; Al-Bahrani B; Burney IA; Al-Habsi H; Ganguly SS; Tanira M
    J Clin Gastroenterol; 2009 Feb; 43(2):152-6. PubMed ID: 18779738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glutathione S-transferase polymorphisms in patients with drug eruption.
    Ateş NA; Tursen U; Tamer L; Kanik A; Derici E; Ercan B; Atik U
    Arch Dermatol Res; 2004 Mar; 295(10):429-33. PubMed ID: 14740231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ABCB1 and GST polymorphisms associated with TP53 status in breast cancer.
    Nordgard SH; Ritchie MD; Jensrud SD; Motsinger AA; Alnaes GI; Lemmon G; Berg M; Geisler S; Moore JH; Lønning PE; Børresen-Dale AL; Kristensen VN
    Pharmacogenet Genomics; 2007 Feb; 17(2):127-36. PubMed ID: 17301692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polymorphism of glutathione S-transferase M1 and T1 gene loci in COPD.
    Mehrotra S; Sharma A; Kumar S; Kar P; Sardana S; Sharma JK
    Int J Immunogenet; 2010 Aug; 37(4):263-7. PubMed ID: 20402821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GST profiling may be useful in the screening for thyroid nodule malignancy.
    Granja F; Morari J; Morari EC; Correa LA; Assumpção LV; Ward LS
    Cancer Lett; 2004 Jun; 209(2):129-37. PubMed ID: 15159014
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Susceptibility to esophageal cancer and genetic polymorphisms in glutathione S-transferases T1, P1, and M1 and cytochrome P450 2E1.
    Lin DX; Tang YM; Peng Q; Lu SX; Ambrosone CB; Kadlubar FF
    Cancer Epidemiol Biomarkers Prev; 1998 Nov; 7(11):1013-8. PubMed ID: 9829710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glutathione S-transferase A1 polymorphisms and acute graft-vs.-host disease in HLA-matched sibling allogeneic hematopoietic stem cell transplantation.
    Kim I; Keam B; Lee KH; Kim JH; Oh SY; Ra EK; Yoon SS; Park SS; Kim CS; Park S; Hong YC; Kim BK
    Clin Transplant; 2007; 21(2):207-13. PubMed ID: 17425746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment.
    Hagleitner MM; Coenen MJ; Gelderblom H; Makkinje RR; Vos HI; de Bont ES; van der Graaf WT; Schreuder HW; Flucke U; van Leeuwen FN; Hoogerbrugge PM; Guchelaar HJ; te Loo DM
    Clin Cancer Res; 2015 Aug; 21(15):3436-41. PubMed ID: 25829401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lysyl oxidase polymorphisms and susceptibility to osteosarcoma.
    Liu Y; Lv B; He Z; Zhou Y; Han C; Shi G; Gao R; Wang C; Yang L; Song H; Yuan W
    PLoS One; 2012; 7(7):e41610. PubMed ID: 22911823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment.
    Hattinger CM; Patrizio MP; Luppi S; Magagnoli F; Picci P; Serra M
    Expert Opin Drug Metab Toxicol; 2019 Apr; 15(4):299-311. PubMed ID: 30822170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.